ATE223909T1 - Sulfamide-metalloprotease inhibitoren - Google Patents

Sulfamide-metalloprotease inhibitoren

Info

Publication number
ATE223909T1
ATE223909T1 AT98907943T AT98907943T ATE223909T1 AT E223909 T1 ATE223909 T1 AT E223909T1 AT 98907943 T AT98907943 T AT 98907943T AT 98907943 T AT98907943 T AT 98907943T AT E223909 T1 ATE223909 T1 AT E223909T1
Authority
AT
Austria
Prior art keywords
sulfamide
metalloprotease inhibitors
metalloprotease
inhibitors
sulfamide metalloprotease
Prior art date
Application number
AT98907943T
Other languages
English (en)
Inventor
Chris Allen Broka
Jeffrey Allen Campbell
Arlindo Lucas Castelhano
Jian Jeffrey Chen
Robert Than Hendricks
Michael Joseph Melnick
Keith Adrian Murray Walker
Original Assignee
Hoffmann La Roche
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26713422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE223909(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche, Agouron Pharma filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE223909T1 publication Critical patent/ATE223909T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C07C307/06—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Detergent Compositions (AREA)
AT98907943T 1997-01-23 1998-01-14 Sulfamide-metalloprotease inhibitoren ATE223909T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3671497P 1997-01-23 1997-01-23
US6220997P 1997-10-16 1997-10-16
PCT/EP1998/000180 WO1998032748A1 (en) 1997-01-23 1998-01-14 Sulfamide-metalloprotease inhibitors

Publications (1)

Publication Number Publication Date
ATE223909T1 true ATE223909T1 (de) 2002-09-15

Family

ID=26713422

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98907943T ATE223909T1 (de) 1997-01-23 1998-01-14 Sulfamide-metalloprotease inhibitoren

Country Status (35)

Country Link
EP (1) EP0958287B2 (de)
JP (1) JP3563411B2 (de)
KR (1) KR100377696B1 (de)
CN (1) CN1093125C (de)
AR (1) AR011425A1 (de)
AT (1) ATE223909T1 (de)
AU (1) AU730127B2 (de)
BG (1) BG103586A (de)
BR (1) BR9807508A (de)
CA (1) CA2278694C (de)
DE (2) DE69807845T2 (de)
DK (1) DK0958287T3 (de)
EA (1) EA002810B1 (de)
ES (2) ES2183331T3 (de)
FR (1) FR2758559A1 (de)
GB (1) GB2321641B (de)
HR (1) HRP980036A2 (de)
HU (1) HUP0000941A3 (de)
ID (1) ID22849A (de)
IL (1) IL130802A0 (de)
IS (1) IS5125A (de)
IT (1) IT1298163B1 (de)
MA (1) MA26467A1 (de)
NO (1) NO313635B1 (de)
NZ (1) NZ336625A (de)
OA (1) OA11078A (de)
PA (1) PA8445301A1 (de)
PE (1) PE57399A1 (de)
PL (1) PL334846A1 (de)
PT (1) PT958287E (de)
TN (1) TNSN98012A1 (de)
TR (1) TR199901765T2 (de)
UY (1) UY24854A1 (de)
WO (1) WO1998032748A1 (de)
YU (1) YU34599A (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
HN2000000052A (es) * 1999-05-28 2001-02-02 Pfizer Prod Inc Hidroxiamidas de acidos 3- (arilsulfonilamino)- tetrahidrofuran-3-carboxilicos.
KR20020005769A (ko) 1999-06-04 2002-01-17 다비드 에 질레스 메탈로프로테이나제의 억제제
TR200202164T2 (tr) 1999-08-18 2002-11-21 Warner-Lambert Company Matris metaloproteinaz inhibitörleri olarak kullanışlı olan hidroksamik asit bileşikleri.
DOP2000000107A (es) 1999-12-01 2002-09-16 Agouron Pharmaceutical Inc Compuestos, composiciones y metodos para estimular el crecimiento y alongamiento de las neuronas
MXPA02008111A (es) 2000-02-21 2002-11-29 Astrazeneca Ab N-hidroxiformamidas substituidas con piperidina y piperazina como inhibidores de metaloproteinasas.
AU2001232113A1 (en) * 2000-02-21 2001-09-03 Astrazeneca Ab Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
US6495358B1 (en) * 2000-04-19 2002-12-17 Wichita State University Sulfamide and bis-sulfamide amino acid derivatives as inhibitors of proteolytic enzymes
US6897237B2 (en) 2000-04-28 2005-05-24 Shionogi & Co. Ltd. MMP-12 inhibitors
US6492171B2 (en) 2000-05-16 2002-12-10 Isis Pharmaceuticals, Inc. Antisense modulation of TERT expression
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
GB0119474D0 (en) 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
WO2003035610A1 (en) * 2001-10-26 2003-05-01 Shionogi & Co., Ltd. Sulfonamide derivative having mmp inhibitory activity
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
BR0308908A (pt) * 2002-04-03 2005-01-04 Topotarget Uk Ltd Composto, composição, uso de um composto, e, métodos para inibir a hdac em uma célula, para o tratamento de uma condição mediada pela hdac, de um condição proliferativa, de câncer e de psorìase
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
CA2485346C (en) 2002-06-12 2013-05-28 Exelixis, Inc. Human adam-10 inhibitors
EP1493445A1 (de) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibierung von Stress-induzierter Liganden-abhängiger EGFR Aktivierung
DE10344936A1 (de) * 2003-09-27 2005-04-21 Aventis Pharma Gmbh Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen
CN1997370B (zh) 2004-05-19 2011-06-01 索尔瓦药物有限公司 N-氨磺酰-n＇-芳基哌嗪类化合物在制备用于预防或治疗肥胖和相关疾病的药物中的用途
EP1799667B1 (de) * 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterozyklische derivate und ihre verwendung als therapeutische wirkstoffe
DE102004060229A1 (de) 2004-12-15 2006-06-29 Sanofi-Aventis Deutschland Gmbh Neue zyklische Harnstoffe als Inhibitoren von Metallproteasen
JPWO2007102392A1 (ja) 2006-03-03 2009-07-23 塩野義製薬株式会社 Ｍｍｐ−１３選択的阻害剤
JPWO2008053913A1 (ja) * 2006-11-02 2010-02-25 塩野義製薬株式会社 Ｍｍｐ−１３を選択的に阻害するスルホニルウレア誘導体
WO2008147764A1 (en) * 2007-05-23 2008-12-04 Array Biopharma, Inc. Mmp inhibitors and methods of use thereof
BRPI0818408B1 (pt) * 2007-10-12 2024-01-09 Basf Se Processos para preparar diamidas sulfúricas e ingredientes herbicidas ativos
FR2947268B1 (fr) 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
US8431538B2 (en) * 2009-07-22 2013-04-30 The Board Of Trustees Of The University Of Illinois HDAC inhibitors and therapeutic methods of using same
AU2012267556B9 (en) * 2011-06-09 2017-05-11 Rhizen Pharmaceuticals Sa Novel compounds as modulators of GPR-119
CN108026057B (zh) 2015-05-22 2021-08-06 株式会社钟根堂 用作选择性组蛋白脱乙酰酶抑制剂的杂环烷基衍生化合物及含其的药物组合物
CA3115038A1 (en) 2018-10-04 2020-04-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Egfr inhibitors for treating keratodermas

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH617318A5 (en) † 1975-09-30 1980-05-30 Ciba Geigy Ag Microbicidal composition.
US5140009A (en) * 1988-02-10 1992-08-18 Tap Pharmaceuticals, Inc. Octapeptide LHRH antagonists
US5114937A (en) * 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
IE68045B1 (en) * 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
WO1993006127A1 (en) * 1991-09-17 1993-04-01 Warner-Lambert Company Novel amino acid prodrug renin inhibitors
GB9211707D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
KR100358813B1 (ko) † 1994-05-04 2003-02-11 노바티스 아게 살균제인n-술포닐및n-술포닐아미노산아미드
DE19507447A1 (de) † 1995-03-03 1996-09-05 Vitronic Dr Ing Stein Bildvera Verfahren und Schaltung zum Erfassen und Weiterleiten von Videobilddaten in einem PC
PT861236E (pt) * 1995-11-13 2002-07-31 Hoechst Ag Acidos alfa-iminohidoxamicos e carboxilicos n-substituidos ciclicos e heterociclicos
ATE225343T1 (de) * 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
FR2748026B1 (fr) * 1996-04-26 1998-06-05 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
NO993587L (no) 1999-09-22
EP0958287B1 (de) 2002-09-11
KR20000070398A (ko) 2000-11-25
CA2278694C (en) 2006-09-26
PA8445301A1 (es) 2001-07-31
ES2136037B1 (es) 2000-11-16
ES2136037A1 (es) 1999-11-01
ITMI980091A1 (it) 1999-07-20
EA002810B1 (ru) 2002-10-31
PL334846A1 (en) 2000-03-27
OA11078A (en) 2003-03-17
HUP0000941A2 (hu) 2001-04-28
UY24854A1 (es) 2000-12-29
TNSN98012A1 (fr) 2005-03-15
KR100377696B1 (ko) 2003-03-29
HRP980036A2 (en) 1998-12-31
PE57399A1 (es) 1999-06-25
CA2278694A1 (en) 1998-07-30
JP3563411B2 (ja) 2004-09-08
AU730127B2 (en) 2001-02-22
NO313635B1 (no) 2002-11-04
YU34599A (sh) 2002-03-18
GB2321641B (en) 2001-04-04
MA26467A1 (fr) 2004-12-20
DE69807845D1 (de) 2002-10-17
PT958287E (pt) 2002-12-31
AR011425A1 (es) 2000-08-16
GB2321641A (en) 1998-08-05
GB9801393D0 (en) 1998-03-18
HUP0000941A3 (en) 2002-06-28
BG103586A (bg) 2000-03-31
FR2758559A1 (fr) 1998-07-24
ES2183331T3 (es) 2003-03-16
CN1093125C (zh) 2002-10-23
AU6614098A (en) 1998-08-18
NZ336625A (en) 2001-04-27
IL130802A0 (en) 2001-01-28
IT1298163B1 (it) 1999-12-20
JP2001523222A (ja) 2001-11-20
NO993587D0 (no) 1999-07-22
DE69807845T2 (de) 2003-06-05
BR9807508A (pt) 2000-03-21
ID22849A (id) 1999-12-09
TR199901765T2 (xx) 1999-10-21
DE19802350A1 (de) 1998-07-30
DK0958287T3 (da) 2003-01-20
EP0958287A1 (de) 1999-11-24
CN1250445A (zh) 2000-04-12
IS5125A (is) 1999-07-22
EP0958287B2 (de) 2008-04-09
EA199900643A1 (ru) 2000-04-24
WO1998032748A1 (en) 1998-07-30

Similar Documents

Publication Publication Date Title
DE69807845D1 (de) Sulfamide-metalloprotease inhibitoren
NO995433D0 (no) Protease-inhibitorer
DE69718480D1 (de) Heterocyclische metalloprotease inhibitoren
NO20012980L (no) Proteaseinhibitorer
ATE226573T1 (de) Heterozyklische metalloproteaseinhibitoren
NO20000464L (no) Acykliske metalloprotease-inhibitorer
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
PT936912E (pt) Inibidores de cisteina protease
ATE237329T1 (de) Metalloprotease inhibitoren
ATE227274T1 (de) 1,3-diheterozyklische metalloprotease inhibitoren
ATE264339T1 (de) Serine protease inhibitoren
NO996578D0 (no) Urokinase-inhibitorer
NO20004550D0 (no) Enzyminhibitorer
NO995435D0 (no) Protease-inhibitorer
NO995434D0 (no) Proteaseinhibitorer
NO995268D0 (no) Proteaseinhibitorer
NO990896D0 (no) Bidentate metalloproteaseinhibitorer
NO20014243D0 (no) Dihetero-substituerte metalloprotease inhibitorer
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
MA26429A1 (fr) Inhibiteurs de protease
NO994415D0 (no) HIV proteaseinhibitorer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0958287

Country of ref document: EP

RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties